Advertisement

A federal appeals court has reversed a lower court decision in a patent dispute over a coronary stent involving Boston Scientific Corp. (NYSE: BSX), ruling that the lower court got it wrong when it ruled in favor of the Natick medical device giant.

Advertisement
Advertisement